Bradley & Co Private Wealth Management’s Standard BioTools LAB Stock Holding History

Bradley & Co Private Wealth Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-179,364	Closed	-$194K	–	196
2025 Q1	$194K	Hold	179,364	–	–	0.13%	42
2024 Q4	$314K	Buy	+179,364	New	+$334K	0.2%	33
2024 Q2	$396K	Sell	223,939 -223,938	-50%	-$547K	0.29%	28
2024 Q1	$1.21M	Buy	447,877 +397,877	+796%	+$961K	0.98%	17
2023 Q4	$111K	Hold	50,000	–	–	0.1%	41
2023 Q3	$145K	Hold	50,000	–	–	0.15%	36
2023 Q2	$96.5K	Hold	50,000	–	–	0.1%	40
2023 Q1	$97.5K	Hold	50,000	–	–	0.11%	38
2022 Q4	$58.5K	Hold	50,000	–	–	0.07%	56
2022 Q3	$55K	Hold	50,000	–	–	0.07%	66
2022 Q2	$80K	Hold	50,000	–	–	0.09%	69
2022 Q1	$180K	Hold	50,000	–	–	0.15%	51
2021 Q4	$196K	Hold	50,000	–	–	0.16%	48
2021 Q3	$330K	Hold	50,000	–	–	0.28%	41
2021 Q2	$308K	Hold	50,000	–	–	0.27%	42
2021 Q1	$226K	Buy	+50,000	New	+$275K	0.21%	48

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bradley & Co Private Wealth Management's LAB Position: Q2 2025 in Review

Bradley & Co Private Wealth Management sold out of Standard BioTools (LAB) in Q2 2025, closing a stake of 179,364 shares — an estimated $194K sold.

Bradley & Co Private Wealth Management first reported a position in LAB in Q1 2021 and held it in 16 quarters. The position peaked at $1.21M in Q1 2024. 160 funds tracked by Wall St. Rank hold LAB as of Q2 2025.

Bradley & Co Private Wealth Management reported no remaining Standard BioTools position as of Q2 2025 after selling out during the quarter.
Bradley & Co Private Wealth Management sold 179,364 Standard BioTools shares in Q2 2025, an estimated $194K.
Bradley & Co Private Wealth Management first reported a position in Standard BioTools in Q1 2021 and held it in 16 quarters.
Bradley & Co Private Wealth Management's Standard BioTools position peaked at $1.21M in Q1 2024.
160 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2025.

Based on Bradley & Co Private Wealth Management's 13F filing for Q2 2025, filed 7 Aug 2025.